vs
LIGAND PHARMACEUTICALS INC（LGND）与RCI HOSPITALITY HOLDINGS, INC.（RICK）财务数据对比。点击上方公司名可切换其他公司
RCI HOSPITALITY HOLDINGS, INC.的季度营收约是LIGAND PHARMACEUTICALS INC的1.2倍（$70.9M vs $59.7M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs -7.8%，领先82.8%），LIGAND PHARMACEUTICALS INC同比增速更快（39.4% vs -3.1%），LIGAND PHARMACEUTICALS INC自由现金流更多（$45.9M vs $11.5M），过去两年LIGAND PHARMACEUTICALS INC的营收复合增速更高（38.8% vs -2.0%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
RCI Hospitality控股通过子公司经营脱衣舞俱乐部、夜总会、运动酒吧与餐厅，同时还运营一家为成人俱乐部行业提供服务的传媒会展企业。公司于1995年完成首次公开募股上市，目前在纳斯达克全球市场挂牌交易。
LGND vs RICK — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $70.9M |
| 净利润 | $44.8M | $-5.5M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | -0.7% |
| 净利率 | 75.1% | -7.8% |
| 营收同比 | 39.4% | -3.1% |
| 净利润同比 | 244.1% | -2354.9% |
| 每股收益（稀释后） | $2.42 | $-0.60 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $59.7M | — | ||
| Q3 25 | $115.5M | $70.9M | ||
| Q2 25 | $47.6M | $71.1M | ||
| Q1 25 | $45.3M | $65.9M | ||
| Q4 24 | $42.8M | $71.5M | ||
| Q3 24 | $51.8M | $73.2M | ||
| Q2 24 | $41.5M | $76.2M | ||
| Q1 24 | $31.0M | $72.3M |
| Q4 25 | $44.8M | — | ||
| Q3 25 | $117.3M | $-5.5M | ||
| Q2 25 | $4.8M | $4.1M | ||
| Q1 25 | $-42.5M | $3.2M | ||
| Q4 24 | $-31.1M | $9.0M | ||
| Q3 24 | $-7.2M | $244.0K | ||
| Q2 24 | $-51.9M | $-5.2M | ||
| Q1 24 | $86.1M | $774.0K |
| Q4 25 | 23.2% | — | ||
| Q3 25 | 47.6% | -0.7% | ||
| Q2 25 | 17.7% | 12.2% | ||
| Q1 25 | -79.9% | 12.4% | ||
| Q4 24 | -22.5% | 19.5% | ||
| Q3 24 | 6.1% | 4.8% | ||
| Q2 24 | -46.0% | -3.3% | ||
| Q1 24 | 9.6% | 6.4% |
| Q4 25 | 75.1% | — | ||
| Q3 25 | 101.6% | -7.8% | ||
| Q2 25 | 10.2% | 5.7% | ||
| Q1 25 | -93.6% | 4.9% | ||
| Q4 24 | -72.6% | 12.6% | ||
| Q3 24 | -13.8% | 0.3% | ||
| Q2 24 | -125.0% | -6.9% | ||
| Q1 24 | 278.1% | 1.1% |
| Q4 25 | $2.42 | — | ||
| Q3 25 | $5.68 | $-0.60 | ||
| Q2 25 | $0.24 | $0.46 | ||
| Q1 25 | $-2.21 | $0.36 | ||
| Q4 24 | $-1.70 | $1.01 | ||
| Q3 24 | $-0.39 | $0.04 | ||
| Q2 24 | $-2.88 | $-0.56 | ||
| Q1 24 | $4.75 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $33.7M |
| 总债务越低越好 | — | $238.2M |
| 股东权益账面价值 | $1.0B | $261.1M |
| 总资产 | $1.6B | $596.9M |
| 负债/权益比越低杠杆越低 | — | 0.91× |
8季度趋势，按日历期对齐
| Q4 25 | $733.5M | — | ||
| Q3 25 | $664.5M | $33.7M | ||
| Q2 25 | $245.0M | $29.3M | ||
| Q1 25 | $208.9M | $32.7M | ||
| Q4 24 | $256.2M | $34.7M | ||
| Q3 24 | $219.6M | $32.4M | ||
| Q2 24 | $226.9M | $34.9M | ||
| Q1 24 | $310.6M | $20.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $238.2M | ||
| Q2 25 | — | $243.8M | ||
| Q1 25 | — | $244.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $241.1M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $950.2M | $261.1M | ||
| Q2 25 | $828.5M | $269.5M | ||
| Q1 25 | $795.5M | $268.8M | ||
| Q4 24 | $830.4M | $269.0M | ||
| Q3 24 | $841.2M | $263.4M | ||
| Q2 24 | $775.2M | $271.2M | ||
| Q1 24 | $806.5M | $285.8M |
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.5B | $596.9M | ||
| Q2 25 | $948.6M | $597.4M | ||
| Q1 25 | $905.4M | $589.8M | ||
| Q4 24 | $941.8M | $586.2M | ||
| Q3 24 | $954.9M | $584.4M | ||
| Q2 24 | $866.4M | $601.0M | ||
| Q1 24 | $913.9M | $609.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.91× | ||
| Q2 25 | — | 0.90× | ||
| Q1 25 | — | 0.91× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.92× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $13.7M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $11.5M |
| 自由现金流率自由现金流/营收 | 76.9% | 16.2% |
| 资本支出强度资本支出/营收 | 0.0% | 3.2% |
| 现金转化率经营现金流/净利润 | 1.03× | — |
| 过去12个月自由现金流最近4个季度 | $48.9M | $34.9M |
8季度趋势，按日历期对齐
| Q4 25 | $45.9M | — | ||
| Q3 25 | $13.1M | $13.7M | ||
| Q2 25 | $15.8M | $13.8M | ||
| Q1 25 | $-25.4M | $8.5M | ||
| Q4 24 | $28.5M | $13.3M | ||
| Q3 24 | $36.5M | $15.7M | ||
| Q2 24 | $13.3M | $15.8M | ||
| Q1 24 | $18.7M | $10.8M |
| Q4 25 | $45.9M | — | ||
| Q3 25 | $13.1M | $11.5M | ||
| Q2 25 | $15.6M | $10.1M | ||
| Q1 25 | $-25.7M | $5.7M | ||
| Q4 24 | $27.8M | $7.6M | ||
| Q3 24 | $35.9M | $10.3M | ||
| Q2 24 | $12.9M | $9.3M | ||
| Q1 24 | $18.6M | $3.2M |
| Q4 25 | 76.9% | — | ||
| Q3 25 | 11.3% | 16.2% | ||
| Q2 25 | 32.7% | 14.2% | ||
| Q1 25 | -56.6% | 8.6% | ||
| Q4 24 | 64.8% | 10.6% | ||
| Q3 24 | 69.4% | 14.0% | ||
| Q2 24 | 31.1% | 12.3% | ||
| Q1 24 | 60.1% | 4.4% |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 3.2% | ||
| Q2 25 | 0.4% | 5.2% | ||
| Q1 25 | 0.5% | 4.3% | ||
| Q4 24 | 1.7% | 8.0% | ||
| Q3 24 | 1.2% | 7.3% | ||
| Q2 24 | 1.0% | 8.4% | ||
| Q1 24 | 0.3% | 10.6% |
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.11× | — | ||
| Q2 25 | 3.26× | 3.40× | ||
| Q1 25 | — | 2.65× | ||
| Q4 24 | — | 1.48× | ||
| Q3 24 | — | 64.14× | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.22× | 14.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RICK
| Transferred At Point In Time | $60.8M | 86% |
| Food And Merchandise | $10.4M | 15% |
